Formerly known as Fifth Base, LLC, AcuityBio,Inc is structured around commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. The companys lead product candidate ABC 103 utilizes the FDA-approved drug paclitaxel with 510(k) cleared components, creating a proprietary solution to prevent post surgical lung cancer recurrence. ABC 103 is designed to be administered at the time of re-section with approved endoscopic cutting staplers as part of standard surgical procedures enabling localized and sustained levels of paclitaxel for more than 60 days to at-risk sites thereby preventing reoccurrence. AcuityBio ABC drug delivery platform technology can Bbe used to deliver many compounds and ABC 103 itself can be safely administered as an adjuvant to immune oncology drugs to enhance their efficacy
